About Veristat
Veristat is a company based in Chatham (United States) founded in 2003 by Kyle McBride, Mark McBride, and Dave Koster was acquired by Veristat in October 2023. It operates as a Professional Services and Managed Services. Veristat offers products and services including Full-Service Clinical Trials, Biometrics, and Regulatory Affairs. Veristat operates in a competitive market with competitors including Medpace, Lambda Therapeutic, Dhiti Life Sciences, JCCT and Ascada Research, among others.
- Headquarter Chatham, United States
- Founders Kyle McBride, Mark McBride, Dave Koster
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Veristat, Llc
- Date of Incorporation 27 Oct, 2015
- Jurisdiction Kanchipuram, Tamil Nadu, India
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Veristat
Veristat offers a comprehensive portfolio of products and services, including Full-Service Clinical Trials, Biometrics, and Regulatory Affairs.
Clinical trials are managed through all development phases.
Clinical trial data is collected, analyzed, and reported.
Regulatory expertise is provided for clinical development phases.
Funding Insights of Veristat
Detailed funding history for Veristat
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Veristat
Veristat has secured backing from 1 investor. Prominent investors backing the company include Veristat.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Clinical trials and regulatory submissions are supported as a CRO.
|
Locked | Locked | Locked |
Investor details for Veristat
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Veristat
Investment portfolio details for Veristat
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Veristat
Detailed financials for Veristat
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Veristat Comparisons
Peer comparison for Veristat
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Veristat
Veristat operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Medpace, Lambda Therapeutic, Dhiti Life Sciences, JCCT and Ascada Research, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
A range of clinical research services is offered by Medpace.
|
|
| Locked | Locked | Locked |
CRO with operations in India, US, Poland, Canada and UK. Winner of Frost & Sullivan 'CRO of the Year' - 2010
|
|
| Locked | Locked | Locked |
Biotechnology company offering in vitro diagnostic products for healthcare sector
|
|
| Locked | Locked | Locked |
CRO focused on early & end stage clinical trial services
|
|
| Locked | Locked | Locked |
Performs clinical research trials to evaluate investigational drugs and devices.
|
|
| Locked | Locked | Locked |
Educational programs are provided by Diacrin since 1989.
|
Detailed competitors of Veristat
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Veristat
Complete news archive for Veristat
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Veristat
Veristat was founded in 2003.
Veristat is headquartered in Chatham, United States.
Kyle McBride is the current CEO of Veristat. They have also founded this company.
Annual revenue of Veristat is $272.39K as on Mar 31, 2022.
Veristat is involved in delivering full-service clinical research solutions and consultancy across the entire lifecycle of therapeutic development. Services are offered in areas such as clinical trial planning, regulatory submissions, and commercialization. Specialized solutions are provided for biologics, rare diseases, and decentralized trials. Expertise is extended to therapeutic areas including oncology, neurology, and infectious diseases. Comprehensive support is given through biometrics, medical writing, and pharmacovigilance to ensure regulatory compliance and patient safety.
Veristat's top competitors include Medpace, Lambda Therapeutic and Dhiti Life Sciences.
Veristat offers Full-Service Clinical Trials, Biometrics, and Regulatory Affairs.
Veristat has 1 investor. Key investors include Veristat.